Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)
Singapore
· Delayed Price · Currency is SGD · Price in USD 2.500
+0.010 (0.40%)
Jun 13, 2025, 5:04 PM SGT
SGX:T14 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 2,216 | 2,229 | 986.71 | 861.79 | 769.14 | 661.7 | Upgrade
|
Depreciation & Amortization | 123.56 | 123.56 | 130.13 | 116.56 | 115.53 | 110.85 | Upgrade
|
Other Amortization | 4.65 | 4.65 | 3.03 | 4.11 | 2.26 | 2.71 | Upgrade
|
Loss (Gain) From Sale of Assets | -0.11 | -0.11 | -0.15 | -1.08 | -12.32 | -7.54 | Upgrade
|
Asset Writedown & Restructuring Costs | 113.8 | 113.8 | 44.36 | 20.16 | 1.93 | 0.92 | Upgrade
|
Loss (Gain) From Sale of Investments | -1,908 | -1,908 | -308.11 | -274.22 | -213.49 | -160.41 | Upgrade
|
Provision & Write-off of Bad Debts | 44.78 | 44.78 | 19.09 | 9.22 | 4.89 | 6.35 | Upgrade
|
Other Operating Activities | 497.29 | 39.39 | 38.92 | 54.02 | 32.68 | 17.81 | Upgrade
|
Change in Accounts Receivable | 26.25 | 26.25 | 74.01 | -732.29 | -42.07 | -113.81 | Upgrade
|
Change in Inventory | 21.95 | 21.95 | -165.34 | 58.87 | -47.4 | 110.96 | Upgrade
|
Change in Accounts Payable | 288.5 | 288.5 | -56.06 | 609.67 | 220.2 | 13.81 | Upgrade
|
Change in Other Net Operating Assets | -0.02 | -0.02 | -18.98 | 6.82 | 10.15 | 9.75 | Upgrade
|
Operating Cash Flow | 1,369 | 924.67 | 688.49 | 677.25 | 852.4 | 671.42 | Upgrade
|
Operating Cash Flow Growth | 232.22% | 34.30% | 1.66% | -20.55% | 26.96% | 35.51% | Upgrade
|
Capital Expenditures | -127.62 | -117.81 | -140.93 | -107.9 | -156.95 | -189.16 | Upgrade
|
Sale of Property, Plant & Equipment | 0.11 | 0.08 | 0.19 | 1.49 | 28.71 | 6.77 | Upgrade
|
Cash Acquisitions | -347.8 | -347.8 | - | -47.61 | - | - | Upgrade
|
Investment in Securities | -1,079 | 451.25 | -606.35 | -65.08 | -334.92 | 41.05 | Upgrade
|
Other Investing Activities | -65.24 | 356.59 | 178.18 | 206.82 | 151.3 | 215.12 | Upgrade
|
Investing Cash Flow | -1,619 | 342.31 | -568.91 | -12.28 | -311.85 | 73.77 | Upgrade
|
Long-Term Debt Issued | - | 1,221 | 870.86 | 205.65 | - | - | Upgrade
|
Total Debt Issued | 921.07 | 1,221 | 870.86 | 205.65 | - | - | Upgrade
|
Long-Term Debt Repaid | - | -522.3 | -807.34 | -39.87 | -1.42 | -1.1 | Upgrade
|
Total Debt Repaid | -522.3 | -522.3 | -807.34 | -39.87 | -1.42 | -1.1 | Upgrade
|
Net Debt Issued (Repaid) | 398.77 | 698.77 | 63.52 | 165.78 | -1.42 | -1.1 | Upgrade
|
Issuance of Common Stock | - | - | - | - | - | 8.36 | Upgrade
|
Repurchase of Common Stock | -3.09 | -3.09 | -22.67 | - | -1.35 | -0.7 | Upgrade
|
Common Dividends Paid | -1,008 | -1,011 | -877.33 | -387.43 | -232.06 | -232.61 | Upgrade
|
Other Financing Activities | -1.85 | -4.98 | 2.7 | -14.96 | -9.87 | -11.21 | Upgrade
|
Financing Cash Flow | -614.55 | -319.89 | -833.77 | -236.62 | -244.7 | -237.26 | Upgrade
|
Foreign Exchange Rate Adjustments | 0.01 | -0.04 | 0.05 | 0.01 | - | - | Upgrade
|
Net Cash Flow | -864.34 | 947.05 | -714.15 | 428.35 | 295.85 | 507.93 | Upgrade
|
Free Cash Flow | 1,242 | 806.86 | 547.56 | 569.34 | 695.45 | 482.26 | Upgrade
|
Free Cash Flow Growth | 311.80% | 47.36% | -3.83% | -18.13% | 44.21% | 66.37% | Upgrade
|
Free Cash Flow Margin | 18.60% | 11.04% | 6.66% | 6.90% | 10.07% | 7.30% | Upgrade
|
Free Cash Flow Per Share | 1.62 | 1.05 | 0.71 | 0.73 | 0.90 | 0.63 | Upgrade
|
Cash Income Tax Paid | 680.66 | 751.63 | 765.94 | 526.93 | 496.73 | 522.98 | Upgrade
|
Levered Free Cash Flow | - | 1,818 | 360.35 | 961.19 | 149.46 | 270.91 | Upgrade
|
Unlevered Free Cash Flow | - | 1,843 | 382.76 | 967.61 | 151.29 | 270.92 | Upgrade
|
Change in Net Working Capital | - | -1,349 | 122.61 | -535.27 | 176.45 | -2.12 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.